

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Attorney Docket No. 2009\_1193

Wei-Ping CHEN et al. : **Confirmation No. 4155**

Serial No. 10/586,287 : Group Art Unit 1762

Filed September 29, 2006 : Examiner Rip A. Lee

NOVEL METALLOCENE-BASED CHIRAL  
PHOSPHINE OR ARSINE LIGANDS : **Mail Stop: AF**

---

**RESPONSE AFTER FINAL REJECTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Responsive to the Office Action of March 2, 2011, Applicants submit the following remarks in support of the patentability of the presently claimed invention over the disclosure of the reference relied upon by the Examiner in rejecting the claims. Further and favorable reconsideration is respectfully requested in view of these remarks.

**Summary of Telephonic Interview**

Applicants wish to kindly thank Examiner Lee for discussing the above-identified application with Applicants' representative on March 15, 2011.

During the interview, Applicants' representative discussed the outstanding double-patenting rejection. Specifically, Applicants' representative discussed the Examiner's statement that both sets of claims (i.e., the claims in the present application and the claims in the reference application) are drawn to the "same process". Applicants' representative noted that many of the claims of the present application are directed to a ligand, rather than a process. The Examiner acknowledged this point.

The Examiner recommended addressing the double patenting rejection by cancelling the method claims or by filing a Terminal Disclaimer.